{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:16:53Z","timestamp":1791404213520,"version":"4.3.3"},"reference-count":107,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,15]]},"DOI":"10.1086\/428055","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T14:36:00Z","timestamp":1115390160000},"page":"S144-S157","source":"Crossref","is-referenced-by-count":319,"title":["Antimicrobial Safety: Focus on Fluoroquinolones"],"prefix":"10.1093","volume":"41","author":[{"suffix":"Jr.","given":"Robert C.","family":"Owens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,7,15]]},"reference":[{"key":"key\n\t\t\t\t20171014013144_ref1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1086\/515104","article-title":"Fluoroquinolone toxicity profiles: a review focusing on newer agents","volume":"28","author":"Lipsky","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00003495-199447040-00008","article-title":"Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014013144_ref3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00126839-200304010-00013","article-title":"Sitafloxacin: DU 6859, DU 6859A, Gracevit, sitafloxacin hydrate","volume":"4","year":"2003","journal-title":"Drugs R D"},{"key":"key\n\t\t\t\t20171014013144_ref4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1592\/phco.22.8.663.33201","article-title":"Torsades de pointes associated with fluoroquinolones","volume":"22","author":"Owens","year":"2002","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171014013144_ref5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/340861","article-title":"Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System","volume":"35","author":"Shaffer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref6","first-page":"442","article-title":"Choosing the ideal antibiotic therapy and the role of the newer fluoroquinolones in respiratory tract infections","volume":"6","author":"Owens","year":"2000","journal-title":"Am J Manag Care"},{"key":"key\n\t\t\t\t20171014013144_ref7","first-page":"5","article-title":"Quinolone structure-activity relationships","volume":"3","author":"Owens","year":"1999","journal-title":"Antibiotic Clin"},{"key":"key\n\t\t\t\t20171014013144_ref8","first-page":"415","article-title":"A profile of gemifloxacin, a new respiratory fluoroquinolone","volume":"21","author":"File","year":"2003","journal-title":"Today's Therapeutic Trends"},{"key":"key\n\t\t\t\t20171014013144_ref9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0149-2918(04)90170-1","article-title":"Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies","volume":"26","author":"Ball","year":"2004","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171014013144_ref10","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/378809","article-title":"Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones","volume":"37","author":"Saravolatz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0732-8893(02)00458-3","article-title":"Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly","volume":"44","author":"Nicholson","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t20171014013144_ref13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/44.4.515","article-title":"Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis","volume":"44","author":"Langan","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/AAC.42.1.114","article-title":"Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily","volume":"42","author":"Chodosh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref15","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0025-7125(05)70297-2","article-title":"Clinical use of the fluoroquinolones","volume":"84","author":"Owens","year":"2000","journal-title":"Med Clin N Am"},{"key":"key\n\t\t\t\t20171014013144_ref16","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1128\/AAC.33.10.1778","article-title":"Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin","volume":"33","author":"Bowie","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref17","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1128\/AAC.33.10.1774","article-title":"Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections","volume":"33","author":"Bowie","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref18","volume-title":"Trovafloxacin (Trovan) [package insert]","year":"1998"},{"key":"key\n\t\t\t\t20171014013144_ref19","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.33.10.1704","article-title":"Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites","volume":"33","author":"Akahane","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure-activity and structure-side-effect relationships for the quinolone antibacterials","volume":"33","author":"Domagala","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref21","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1128\/AAC.43.6.1511","article-title":"Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats","volume":"43","author":"Delon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1345\/aph.1D349","article-title":"Possible gatifloxacin-induced seizure","volume":"38","author":"Quigley","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171014013144_ref23","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00003495-200464100-00005","article-title":"QT prolongation with antimicrobial agents: understanding the significance","volume":"64","author":"Owens","year":"2004","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014013144_ref24","volume-title":"International Conference on Harmonization S7B Document","author":"Safety pharmacology studies assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","year":"2002"},{"key":"key\n\t\t\t\t20171014013144_ref25","volume-title":"Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products","author":"European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products","year":"1997"},{"key":"key\n\t\t\t\t20171014013144_ref26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1592\/phco.21.3.301.34206","article-title":"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes","volume":"21","author":"Owens","year":"2001","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171014013144_ref27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1086\/339075","article-title":"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors","volume":"34","author":"Bertino","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(00)80728-X","article-title":"MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia","volume":"97","author":"Abbott","year":"1999","journal-title":"Cell"},{"key":"key\n\t\t\t\t20171014013144_ref29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1540-8159.1998.tb00148.x","article-title":"Taking the \u201cidio\u201d out of \u201cidiosyncratic\u201d: predicting torsades de pointes","volume":"21","author":"Roden","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"key":"key\n\t\t\t\t20171014013144_ref30","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0025-7125(05)70296-0","article-title":"Antimicrobial pharmacodynamics","volume":"84","author":"Ambrose","year":"2000","journal-title":"Med Clin North Am"},{"key":"key\n\t\t\t\t20171014013144_ref31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(03)00061-8","article-title":"Clinical pharmacodynamics of quinolones","volume":"17","author":"Ambrose","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20171014013144_ref32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0149-2918(04)90170-1","article-title":"Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies","volume":"26","author":"Ball","year":"2004","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171014013144_ref33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.1C066","article-title":"Clinical experience with moxifloxacin in patients with respiratory tract infections","volume":"38","author":"Faich","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171014013144_ref34","first-page":"430","article-title":"Ciprofloxacin-induced QTc prolongation","volume":"50","author":"Singh","year":"2002","journal-title":"J Assoc Physicians India"},{"key":"key\n\t\t\t\t20171014013144_ref35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1476-5381.1996.tb15201.x","article-title":"Increase in insulin release from rat pancreatic islets by quinolone antibiotics","volume":"117","author":"Maeda","year":"1996","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20171014013144_ref36","volume-title":"Tequin (gatifloxacin) [package insert]","year":"2002"},{"key":"key\n\t\t\t\t20171014013144_ref37","volume-title":"Levaquin (levofloxacin) [package insert]","year":"2003"},{"key":"key\n\t\t\t\t20171014013144_ref38","volume-title":"Avelox (moxifloxacin) [package insert]","year":"2003"},{"key":"key\n\t\t\t\t20171014013144_ref39","volume-title":"Cipro (ciprofloxacin) [package insert]","year":"2003"},{"key":"key\n\t\t\t\t20171014013144_ref40","volume-title":"Factive (gemifloxacin) [package insert]","year":"2003"},{"key":"key\n\t\t\t\t20171014013144_ref41","first-page":"148","article-title":"Effect of clinafloxacin on serum insulin and glucose levels in healthy subjects","volume":"61","author":"Shailer","year":"1997","journal-title":"Clin Pharm Ther"},{"key":"key\n\t\t\t\t20171014013144_ref42","article-title":"Safety of clinafloxacin, a new fluoroquinolone antibiotic [abstract 1764]","volume-title":"Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco)","author":"Welling","year":"1999"},{"key":"key\n\t\t\t\t20171014013144_ref43","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2165\/00003495-199447060-00003","article-title":"Quinolone antibacterials: an update of their pharmacology and therapeutic use","volume":"47","author":"von Rosenstiel","year":"1994","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014013144_ref44","volume-title":"Diabeta (glyburide) [package insert]","year":"2003"},{"key":"key\n\t\t\t\t20171014013144_ref45","first-page":"378","article-title":"Study of interaction between oral ciprofloxacin and glibenclamide","volume":"4","author":"Ludwig","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1067\/mem.2000.108617","article-title":"Glyburide-ciprofloxacin interaction with resistant hypoglycemia","volume":"36","author":"Roberge","year":"2000","journal-title":"Ann Emerg Med"},{"key":"key\n\t\t\t\t20171014013144_ref47","article-title":"Lack of effect of multiple-dose gatifloxacin on oral glucose tolerance, glucose and insulin homeostasis, and glyburide pharmacokinetics in patients with type II non-insulin-dependent diabetes mellitus [abstract]","volume-title":"Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco)","author":"Grasela","year":"1999"},{"key":"key\n\t\t\t\t20171014013144_ref48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1592\/phco.20.8.76S.35182","article-title":"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise","volume":"20","author":"Gajjar","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171014013144_ref49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1086\/319376","article-title":"Profile of moxifloxacin drug interactions","volume":"32","author":"Stass","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref50","first-page":"64","article-title":"Hypoglycemia and hyperglycemia with fluoroquinolones","volume":"45","year":"2003","journal-title":"Med Lett Drugs Ther"},{"key":"key\n\t\t\t\t20171014013144_ref51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1345\/aph.1D360","article-title":"Possible gatifloxacin-induced hyperglycemia","volume":"38","author":"Donaldson","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171014013144_ref52","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/jac\/dkg370","article-title":"Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction","volume":"52","author":"Ambrose","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref53","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00002018-200427090-00005","article-title":"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies","volume":"27","author":"Gavin","year":"2004","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t20171014013144_ref54","volume-title":"New drug applications. Rates of hypoglycemia","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t20171014013144_ref55","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1532-5415.1998.tb02752.x","article-title":"Hypoglycemia in hospitalized nondiabetic older patients","volume":"46","author":"Shilo","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t20171014013144_ref56","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1001\/archinte.163.15.1825","article-title":"Hypoglycemia as a predictor of mortality in hospitalized elderly patients","volume":"163","author":"Kagansky","year":"2003","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20171014013144_ref57","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1086\/516119","article-title":"Quinolone arthropathy in animals versus children","volume":"25","author":"Burkhardt","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref58","first-page":"307","article-title":"Proteoglycan and procollagen synthesis in rat embryo limb bud cultures treated with quinolone antibacterials","volume":"7","author":"Amacher","year":"1989","journal-title":"Altern Methods Toxicol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014013144_ref59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003495-199958002-00007","article-title":"Toxicity of quinolones","volume":"58","author":"Stahlmann","year":"1999","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014013144_ref60","first-page":"75","article-title":"Features of tendon disorders with fluoroquinolones","volume":"49","author":"Royer","year":"1994","journal-title":"Therapie"},{"key":"key\n\t\t\t\t20171014013144_ref61","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bmj.324.7349.1306","article-title":"Fluoroquinolones and risk of Achilles tendon disorders: case-control study","volume":"324","author":"van der Linden","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20171014013144_ref62","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1001\/archinte.163.15.1801","article-title":"Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids","volume":"163","author":"van der Linden","year":"2003","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014013144_ref63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2165\/00003495-199958002-00135","article-title":"Effects of ofloxacin on ultrastructure of Achilles tendon in rats","volume":"58","author":"Shakibaei","year":"1999","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014013144_ref64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1011-1344(96)07424-6","article-title":"Fluoroquinolone antibacterials enhance UVA-induced skin tumors","volume":"37","author":"Klecak","year":"1997","journal-title":"J Photochem Photobiol B"},{"key":"key\n\t\t\t\t20171014013144_ref65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0923-1811(98)00026-7","article-title":"Quinolone photoallergy: photosensitivity dermatitis induced by systemic administration of photohaptenic drugs","volume":"18","author":"Tokura","year":"1998","journal-title":"J Dermatol Sci"},{"key":"key\n\t\t\t\t20171014013144_ref66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00130832-200308000-00007","article-title":"Quinolone hypersensitivity","volume":"3","author":"Campi","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20171014013144_ref67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2003.09.035","article-title":"Detection of specific IgE to quinolones","volume":"113","author":"Manfredi","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20171014013144_ref68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1398-9995.1993.tb02413.x","article-title":"Cross-reactivity between quinolones: report of three cases","volume":"48","author":"Davila","year":"1993","journal-title":"Allergy"},{"key":"key\n\t\t\t\t20171014013144_ref69","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/bmj.298.6673.605-b","article-title":"Fatal anaphylaxis associated with ciprofloxacin in a patient with AIDS related complex","volume":"298","author":"Peters","year":"1989","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20171014013144_ref70","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0091-6749(96)70218-X","article-title":"Ciprofloxacin desensitization","volume":"97","author":"Gea-Banacloche","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20171014013144_ref71","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0091-6749(95)70240-7","article-title":"Ciprofloxacin desensitization in a patient with cystic fibrosis","volume":"96","author":"Lantner","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20171014013144_ref72","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF01837910","article-title":"Flush induced by fluoroquinolones in canine skin","volume":"44","author":"Kurata","year":"1995","journal-title":"Inflamm Res"},{"key":"key\n\t\t\t\t20171014013144_ref73","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/clinids\/18.6.946","article-title":"Temafloxacin syndrome: review of 95 cases","volume":"18","author":"Blum","year":"1994","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref74","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0378-4274(01)00509-4","article-title":"Clinical toxicological aspects of fluoroquinolones","volume":"127","author":"Stahlmann","year":"2002","journal-title":"Toxicol Lett"},{"key":"key\n\t\t\t\t20171014013144_ref75","first-page":"618","article-title":"Drug-induced pneumonitis with eosinophilic infiltration due to tosufloxacin tosilate [in Japanese]","volume":"36","author":"Kimura","year":"1998","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"key\n\t\t\t\t20171014013144_ref76","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/381551","article-title":"Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use","volume":"38","author":"Gaynes","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref77","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0195-6701(02)00400-0","article-title":"Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection","volume":"54","author":"Wilcox","year":"2003","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20171014013144_ref78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/422523","article-title":"Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile","volume":"39","author":"Apisarnthanarak","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref79","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1086\/424667","article-title":"Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection?","volume":"39","author":"Hota","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref80","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1056\/NEJM198901263200402","article-title":"Nosocomial acquisition of Clostridium difficile infection","volume":"320","author":"McFarland","year":"1989","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014013144_ref81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0195-6701(98)90019-6","article-title":"Risk factors for Clostridium difficile infection","volume":"40","author":"Bignardi","year":"1998","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20171014013144_ref82","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1086\/382084","article-title":"Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem","volume":"38","author":"Gerding","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"key\n\t\t\t\t20171014013144_ref83","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/clinids\/16.Supplement_4.S239","article-title":"Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile","volume":"16","author":"Mulligan","year":"1993","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref84","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1086\/520276","article-title":"Clostridium difficile-associated diarrhea","volume":"26","author":"Johnson","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref85","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3201\/eid0906.020385","article-title":"Fluoroquinolone use and Clostridium difficile-associated diarrhea","volume":"9","author":"McCusker","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref86","first-page":"113","article-title":"Clostridium difficile infection associated with levofloxacin treatment","volume":"95","author":"Ozawa","year":"2002","journal-title":"Tenn Med"},{"key":"key\n\t\t\t\t20171014013144_ref87","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1086\/501954","article-title":"Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea","volume":"22","author":"Yip","year":"2001","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171014013144_ref88","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1086\/503451","article-title":"Ciprofloxacin and Clostridium difficile-associated diarrhea","volume":"23","author":"Thomas","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171014013144_ref89","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0195-6701(98)90257-2","article-title":"Antimicrobial associations of an outbreak of diarrhoea due to Clostridium difficile","volume":"39","author":"Zadik","year":"1998","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20171014013144_ref90","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1503\/cmaj.1041104","article-title":"Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity","volume":"171","author":"Pepin","year":"2004","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20171014013144_ref91","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1046\/j.1365-2036.1998.00428.x","article-title":"Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam","volume":"12","author":"Settle","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014013144_ref92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00003495-199958002-00013","article-title":"Effect of quinolones on intestinal ecology","volume":"58","author":"Edlund","year":"1999","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014013144_ref93","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-0773.1972.tb03610.x","article-title":"Metabolism of xenobiotics by strains of intestinal bacteria","volume":"31","author":"Soleim","year":"1972","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"key\n\t\t\t\t20171014013144_ref94","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJM198110013051403","article-title":"Inactivation of digoxin by the gut flora: reversal by antibiotic therapy","volume":"305","author":"Lindenbaum","year":"1981","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014013144_ref95","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/gut.30.7.971","article-title":"Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora","volume":"30","author":"Mathan","year":"1989","journal-title":"Gut"},{"key":"key\n\t\t\t\t20171014013144_ref96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2000-9927","article-title":"New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins","volume":"21","author":"Ambrose","year":"2002","journal-title":"Semin Resp Crit Care Med"},{"key":"key\n\t\t\t\t20171014013144_ref97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-199701000-00036","article-title":"Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use\u2014safety report","volume":"16","author":"Hampel","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20171014013144_ref98","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.inf.0000101994.25947.12","article-title":"Safety profile of quinolone antibiotics in the pediatric population","volume":"22","author":"Grady","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20171014013144_ref99","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.inf.0000095193.42502.d1","article-title":"Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure","volume":"22","author":"Arguedas","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20171014013144_ref100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002512-200320040-00005","article-title":"Fluoroquinolones in the elderly: safety considerations","volume":"20","author":"Stahlmann","year":"2003","journal-title":"Drugs Aging"},{"key":"key\n\t\t\t\t20171014013144_ref101","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00075198-200210000-00011","article-title":"Optimizing antimicrobial dosing in the critically ill patient","volume":"8","author":"Goldberg","year":"2002","journal-title":"Curr Opin Crit Care"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20171014013144_ref102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003495-199958002-00009","article-title":"Quinolones in the aged","volume":"58","author":"Nicolle","year":"1999","journal-title":"Drugs"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171014013144_ref103","first-page":"s106","article-title":"Pharmacokinetics of ofloxacin in younger and elderly patients [abstract]","volume":"10","author":"Graber","year":"1988","journal-title":"Rev Infect Dis"},{"key":"key\n\t\t\t\t20171014013144_ref104","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1128\/AAC.41.7.1562","article-title":"Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects","volume":"41","author":"Chien","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014013144_ref105","first-page":"155","article-title":"Pharmacodynamics of fluoroquinolones","volume-title":"Antimicrobial pharmacodynamics in theory and clinical practice","author":"Owens","year":"2001"},{"key":"key\n\t\t\t\t20171014013144_ref106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-200059010-00010","article-title":"Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections","volume":"59","author":"Balfour","year":"2000","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014013144_ref107","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00002512-199404020-00007","article-title":"Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly","volume":"4","author":"Wiseman","year":"1994","journal-title":"Drugs Aging"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/41\/Supplement_2\/S144\/20906806\/41-Supplement_2-S144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:24:50Z","timestamp":1550449490000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/41\/Supplement_2\/S144\/308000\/Antimicrobial-Safety-Focus-on-Fluoroquinolones"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,15]]},"references-count":107,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2005,7,15]]},"published-print":{"date-parts":[[2005,7,15]]}},"URL":"https:\/\/doi.org\/10.1086\/428055","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,7,15]]},"published":{"date-parts":[[2005,7,15]]}}}